Independent Drug-Pricing Assessment Finds Vascepa® (icosapent ethyl) Cost-Effective as an Adjunct to Statins in Treating Patients at High Risk of Cardiovascular Events, such as Heart Attack, Stroke and Cardiac Death Read more about Independent Drug-Pricing Assessment Finds Vascepa® (icosapent ethyl) Cost-Effective as an Adjunct to Statins in Treating Patients at High Risk of Cardiovascular Events, such as Heart Attack, Stroke and Cardiac Death
Can pleiotropic effects of eicosapentaenoic acid (EPA) impact residual cardiovascular risk? Read more about Can pleiotropic effects of eicosapentaenoic acid (EPA) impact residual cardiovascular risk?
Comparing eicosapentaenoic acid between plasma and serum from a randomized, controlled clinical trial Read more about Comparing eicosapentaenoic acid between plasma and serum from a randomized, controlled clinical trial
Effects of eicosapentaenoic acid and docosahexaenoic acid on low-density lipoprotein cholesterol and other lipids: a review. Read more about Effects of eicosapentaenoic acid and docosahexaenoic acid on low-density lipoprotein cholesterol and other lipids: a review.
A new pure O-3 eicosapentaenoic acid ethyl ester (AMR101) for the management of hypertriglyceridemia: the MARINE trial Read more about A new pure O-3 eicosapentaenoic acid ethyl ester (AMR101) for the management of hypertriglyceridemia: the MARINE trial
The editor's roundtable: hypertriglyceridemia Read more about The editor's roundtable: hypertriglyceridemia
Icosapent ethyl for the treatment of hypertriglyceridemia Read more about Icosapent ethyl for the treatment of hypertriglyceridemia
Update on marine omega-3 fatty acids: management of dyslipidemia and current omega-3 treatment options Read more about Update on marine omega-3 fatty acids: management of dyslipidemia and current omega-3 treatment options